1 active not recruiting, 1 completed, 1 unknown. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
Follow Deafness, Autosomal Recessive 39: new trials by email Literature Review of Deafness, Autosomal Recessive 39 trials Research Report on Deafness, Autosomal Recessive 39
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer REGN5093 - NSCLC | Phase 1 / Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 95 | 2020-01-07 | 2026-09-16 |
| Phase I/II Study of KP-100IT in Acute Spinal Cord Injury KP-100IT, Placebo - Spinal Cord Injuries | Phase 1 / Phase 2 | Completed | Kringle Pharma, Inc. | 45 | 2014-06-30 | 2019-06-05 |
| Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease Ad-HGF - Ischemic Heart Disease | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 40 | 2012-11-01 | 2013-08-20 |
Adenoviridae Infections (1) · Carcinoma, Non-Small-Cell Lung (1) · Myocardial Ischemia (1) · Neoplasm Metastasis (1) · Spinal Cord Injuries (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · DNA Virus Infections (1) · Heart Diseases (1) · Infections (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Nervous System Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Kringle Pharma, Inc. (1) · Regeneron Pharmaceuticals (1) · The First Affiliated Hospital with Nanjing Medical University (1)
China (1) · France (1) · Japan (1) · South Korea (1) · United States (1)
2019 (1), 2023 (1)